{"id":"apretude-cabotegravir","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site reactions (pain, erythema, induration)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2403238","moleculeType":"Small molecule","molecularWeight":"405.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabotegravir binds to HIV integrase and inhibits the strand transfer step of viral integration into the host genome. By blocking this critical step in the HIV replication cycle, the drug prevents establishment of persistent infection. Apretude is a long-acting injectable formulation designed for HIV pre-exposure prophylaxis (PrEP) and treatment, administered as an intramuscular injection.","oneSentence":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:40.596Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 pre-exposure prophylaxis (PrEP) in at-risk individuals"},{"name":"HIV-1 treatment in combination antiretroviral therapy"}]},"trialDetails":[{"nctId":"NCT07199335","phase":"PHASE4","title":"Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-02-24","conditions":"HIV, Substance Use Disorder (SUD), Injection Drug Use","enrollment":100},{"nctId":"NCT05986084","phase":"PHASE4","title":"Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2023-11-30","conditions":"Pre-Exposure Prophylaxis (PrEP), Breast Feeding","enrollment":500},{"nctId":"NCT05514509","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-10-28","conditions":"HIV Infections","enrollment":370},{"nctId":"NCT06134362","phase":"PHASE3","title":"Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-05-14","conditions":"HIV Infections","enrollment":3508},{"nctId":"NCT05374525","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-05-18","conditions":"HIV Infections","enrollment":287},{"nctId":"NCT06145854","phase":"","title":"Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Midway Specialty Care Center","startDate":"2024-01-02","conditions":"Hiv","enrollment":100},{"nctId":"NCT05867212","phase":"","title":"Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.","status":"COMPLETED","sponsor":"Kelley-Ross & Associates, Inc.","startDate":"2023-05-13","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT05072093","phase":"PHASE4","title":"Parrying the Pitfalls of PrEP: Project PEACH","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-11-20","conditions":"HIV, STI","enrollment":240},{"nctId":"NCT05755204","phase":"","title":"A Pharmacist-run PrEP Program for Women","status":"TERMINATED","sponsor":"Orlando Immunology Center","startDate":"2023-06-21","conditions":"HIV Prevention","enrollment":2},{"nctId":"NCT06807736","phase":"","title":"PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.","status":"RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2024-02-13","conditions":"HIV Infection, Sexual and Reproductive Health","enrollment":1800},{"nctId":"NCT05515770","phase":"PHASE3","title":"The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir","status":"RECRUITING","sponsor":"Evandro Chagas National Institute of Infectious Disease","startDate":"2022-09-20","conditions":"HIV Infections","enrollment":1200},{"nctId":"NCT06138600","phase":"PHASE3","title":"Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2023-11-01","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT06250504","phase":"PHASE3","title":"Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT","status":"RECRUITING","sponsor":"Africa Health Research Institute","startDate":"2024-02-27","conditions":"HIV Infections","enrollment":2000},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT05949203","phase":"","title":"Oregon PrEP at Home Study","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2023-12-01","conditions":"HIV/AIDS","enrollment":125}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"NAUSEA"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ABNORMAL DREAMS"},{"count":1,"reaction":"ABSCESS LIMB"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"CELLULITIS STAPHYLOCOCCAL"},{"count":1,"reaction":"CONTUSION"},{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DISORIENTATION"}],"_approvalHistory":[],"publicationCount":884,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"APRETUDE (cabotegravir)","genericName":"APRETUDE (cabotegravir)","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabotegravir is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into human DNA. Used for HIV-1 prevention in at-risk individuals (pre-exposure prophylaxis, PrEP), HIV-1 treatment in combination antiretroviral therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}